Technical Analysis for GLSI - Greenwich LifeSciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | -2.69% | |
180 Bullish Setup | Bullish Swing Setup | -2.69% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -2.69% | |
Calm After Storm | Range Contraction | -2.69% | |
NR7 | Range Contraction | -2.69% | |
Upper Bollinger Band Walk | Strength | -2.69% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 13 hours ago |
Bullish 180 Entry | about 13 hours ago |
Non-ADX 1,2,3,4 Pullback Entry | about 13 hours ago |
1,2,3, Pullback Entry | about 13 hours ago |
Rose Above Previous Day's High | about 13 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/14/2023
Greenwich LifeSciences, Inc. Description
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Immunotherapy Surgery Cancer Treatment Breast Cancer Clinical Trial Treatment Of Breast Cancer Her2 Her2/Neu Cancer Center
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 20.75 |
52 Week Low | 7.58 |
Average Volume | 51,616 |
200-Day Moving Average | 10.22 |
50-Day Moving Average | 11.34 |
20-Day Moving Average | 14.57 |
10-Day Moving Average | 16.42 |
Average True Range | 1.68 |
RSI (14) | 62.83 |
ADX | 48.13 |
+DI | 33.58 |
-DI | 12.26 |
Chandelier Exit (Long, 3 ATRs) | 15.71 |
Chandelier Exit (Short, 3 ATRs) | 14.95 |
Upper Bollinger Bands | 19.20 |
Lower Bollinger Band | 9.94 |
Percent B (%b) | 0.77 |
BandWidth | 63.57 |
MACD Line | 1.88 |
MACD Signal Line | 1.63 |
MACD Histogram | 0.2444 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 18.23 | ||||
Resistance 3 (R3) | 18.33 | 18.03 | 18.03 | ||
Resistance 2 (R2) | 18.03 | 17.73 | 17.98 | 17.96 | |
Resistance 1 (R1) | 17.53 | 17.54 | 17.38 | 17.43 | 17.90 |
Pivot Point | 17.23 | 17.23 | 17.16 | 17.18 | 17.23 |
Support 1 (S1) | 16.73 | 16.93 | 16.58 | 16.63 | 16.16 |
Support 2 (S2) | 16.43 | 16.74 | 16.38 | 16.10 | |
Support 3 (S3) | 15.93 | 16.43 | 16.03 | ||
Support 4 (S4) | 15.83 |